Hybio Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Hybio Pharmaceutical has a total shareholder equity of CN¥730.4M and total debt of CN¥1.9B, which brings its debt-to-equity ratio to 253.5%. Its total assets and total liabilities are CN¥3.1B and CN¥2.4B respectively.
Key information
253.5%
Debt to equity ratio
CN¥1.85b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥137.76m |
| Equity | CN¥730.42m |
| Total liabilities | CN¥2.39b |
| Total assets | CN¥3.12b |
Recent financial health updates
Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt
Jul 20
Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?
Feb 26Recent updates
Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 26% Price Boost Is Out Of Tune With Revenues
Dec 20Investor Optimism Abounds Hybio Pharmaceutical Co., Ltd. (SZSE:300199) But Growth Is Lacking
Sep 30Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt
Jul 20Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Price Is Out Of Tune With Revenues
Jun 03Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Surge Not Quite Adding Up
Feb 29Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?
Feb 26Financial Position Analysis
Short Term Liabilities: 300199's short term assets (CN¥548.0M) do not cover its short term liabilities (CN¥1.3B).
Long Term Liabilities: 300199's short term assets (CN¥548.0M) do not cover its long term liabilities (CN¥1.1B).
Debt to Equity History and Analysis
Debt Level: 300199's net debt to equity ratio (234.6%) is considered high.
Reducing Debt: 300199's debt to equity ratio has increased from 73% to 253.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 300199 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 300199 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 30.2% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 17:16 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hybio Pharmaceutical Co., Ltd. is covered by 19 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhouyu Deng | BOCI Research Ltd. |
| Yalei Yan | Bohai Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |